Jiangsu Jibeier Pharmaceutical Co (688566) Fair Value & Analysis

Healthcare · CN · Market cap 4.9B CNY

Analysis

Jiangsu Jibeier Pharmaceutical Co (688566) currently trades at ¥24.71, while our model-based Fair Value estimate is ¥22.63 — implying the stock looks roughly 8.4% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Jiangsu Jibeier Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the drug research and development and production in China. The company's products cover multiple therapeutic areas such as increasing white blood cells, fighting hypertension, enhancing immunity, treating joint diseases, fighting eye infections, treating bronchitis, protecting liver function, etc. It is also developing drugs for the treatment of depression, tumors, stomach and gastric diseases, and other diseases. In addition, the company offers its products in tablets, capsules, and eye drops forms. Jiangsu Jibeier Pharmaceutical Co., Ltd. was founded in 2001 and is based in Zhenjiang, China.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.